CIGB-814 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CIGB-814’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CIGB-814 overview

CIGB-814 is under investigation for the treatment of rheumatoid arthritis (RA). It is a synthetic peptide administered subcutaneously. It acts by targeting heat shock protein 60.

Center for Genetic Engineering and Biotechnology overview

Center for Genetic Engineering and Biotechnology (CIGB) is a biotechnology company that investigates, develops, produces and markets novel biotechnological applications, therapeutic and diagnostic biopharmaceutical products, for the biomedical, agricultural and industrial sectors. CIGB is headquartered in Cuba.

For a complete picture of CIGB-814’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.